Humacyte director granted 80,000 stock options
Humacyte, Inc. director Charles Bruce Green received a grant of stock options covering 80,000 shares of common stock.
Rhea-AI Filing Summary
Humacyte, Inc. director Charles Bruce Green received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 stock options directly.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments through June 11, 2030. This is a compensation-related award rather than an open-market share purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
1 txn
Insider
Green Charles Bruce
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 80,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (right to buy) — 80,000 contracts (Direct)
Footnotes (1)
- F1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.
Key Figures
Options granted: 80,000 options
Exercise price: $1.08 per share
Underlying shares: 80,000 shares
+4 more
7 metrics
Options granted
80,000 options
Stock options grant to director on June 11, 2026
Exercise price
$1.08 per share
Exercise price of the granted options
Underlying shares
80,000 shares
Common stock underlying the options
Post-grant option holdings
80,000 options
Total options held following the transaction
Initial vesting date
June 11, 2027
First 25% of options become exercisable
Final vesting date
June 11, 2030
Monthly vesting completes
Expiration date
June 11, 2036
Options expire if unexercised
Key Terms
Stock Options, exercise price, vesting, expiration date
4 terms
Stock Options financial
"director Charles Bruce Green received a grant of stock options covering 80,000 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"The options have an exercise price of $1.08 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The granted stock options expire on June 11, 2036"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Humacyte (HUMA) disclose for Charles Bruce Green?
Humacyte disclosed that director Charles Bruce Green received a grant of 80,000 stock options. These options give him the right to buy Humacyte common shares at a fixed price, functioning as equity-based compensation rather than an immediate stock purchase or sale.
How many Humacyte (HUMA) stock options were granted and at what exercise price?
Charles Bruce Green was granted 80,000 stock options with an exercise price of $1.08 per share. This price is what he would pay per share if he chooses to exercise the options once they vest and become exercisable in the future.
When do Charles Bruce Green’s Humacyte (HUMA) stock options start vesting?
The first 25% of Charles Bruce Green’s 80,000 Humacyte stock options become exercisable on June 11, 2027. After that initial vesting date, additional portions of the options vest monthly, gradually increasing how many options he can exercise over time.
What is the vesting schedule for the new Humacyte (HUMA) stock option grant?
The grant vests with 25% of the options becoming exercisable on June 11, 2027. The remaining 75% then vests in equal 1/48th monthly installments each month on the 11th, continuing through June 11, 2030, creating a four-year vesting pattern overall.
When do the newly granted Humacyte (HUMA) stock options expire?
The granted stock options expire on June 11, 2036. If Charles Bruce Green does not exercise any vested options by that date, his right to buy Humacyte shares at the $1.08 exercise price will lapse and the options will become worthless.
Is this Humacyte (HUMA) Form 4 filing a stock purchase or sale?
This Form 4 reports a grant of stock options, not an open-market stock purchase or sale. It reflects equity compensation to a director, giving a future right to buy shares at $1.08 once vesting conditions are met and the options become exercisable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
